Financial Performance Expectations - The company expects a net profit of between 23 million and 34.5 million yuan for 2024, representing a year-on-year increase of 115.45% compared to a loss of 148.89 million yuan in the previous year[4]. - The net profit after deducting non-recurring gains and losses is projected to be between 8.9 million and 20.4 million yuan, marking a growth of 105.77% to 113.22% from a loss of 154.30 million yuan last year[4]. - The estimated operating revenue for the reporting period is 1.3 billion yuan, an increase of 111 million yuan compared to the previous year, primarily due to better progress in engineering projects[7]. - Basic earnings per share are expected to be between 0.0272 yuan and 0.0408 yuan, compared to a loss of 0.1762 yuan per share in the previous year[4]. Cost Management - Management expenses have been reduced by approximately 30 million yuan, a decrease of 21% compared to the same period last year[6]. - The company has reduced asset impairment losses and credit impairment losses by approximately 60 million yuan, a decrease of 50.44% compared to the previous year[6]. Legal and Regulatory Matters - The company is currently facing arbitration regarding land use rights and potential compensation claims totaling approximately 357.8 million yuan[8]. - The company is actively communicating with local government regarding the arbitration matter and is working on a preliminary resolution plan[9]. Disclosure and Reporting - The financial data in the earnings forecast has not been audited, and the final figures will be disclosed in the 2024 annual report[10]. - The company emphasizes the importance of following official disclosures in designated media for accurate information[11].
尚荣医疗(002551) - 2024 Q4 - 年度业绩预告